Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pandemic influenza alphavaccine H1B + H5
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pandemic influenza alphavaccine H1B + H5 is a bivalent RNA-based vaccine candidate developed by AlphaVax using its proprietary Venezuelan Equine Encephalitis (VEE) Replicon Particle (VRP) technology. The vaccine consists of non-propagating replicon particles that deliver self-amplifying RNA encoding the hemagglutinin (HA) antigens of H1B and H5 influenza strains. Upon administration, the VRPs deliver the genetic instructions into host cells, where the RNA replicates and expresses the target antigens. This process triggers a robust immune response, including the production of neutralizing antibodies and the activation of T-cells, designed to provide rapid and effective protection against potential pandemic influenza strains. The candidate has been evaluated in Phase 1/2 clinical trials.
- Other names
- Pandemic Influenza AlphavaccineAlphaVax Influenza H1B + H5 vaccineH1B + H5 VRP vaccinePandemic Influenza (H1B & H5)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on pandemic influenza alphavaccine H1B + H5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pandemic influenza alphavaccine H1B + H5.